Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 20Neoplasms, Hormone-Dependent 2Neoplasm Metastasis 2Carcinoma, Lobular 2Carcinoma, Ductal, Breast 2Hot Flashes 1Endometrial Neoplasms 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × Aromatase Inhibitors × Clear all
NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Pfizer

Completed
779 enrolled 9 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01446159 2020-06-02

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

MedImmune LLC

Phase 2 Completed
188 enrolled 32 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡